BioMarin Pharmaceutical Inc (BMRN) Actualités

Form 8-K - Current report

BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance

BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance PR Newswire SAN...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET

BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday...

BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court PR Newswire SAN...

BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA

BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT...

Form 4 - Statement of changes in beneficial ownership of securities

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

BioMarin to Participate in Three Upcoming Investor Conferences

BioMarin to Participate in Three Upcoming Investor Conferences PR Newswire SAN RAFAEL, Calif., Nov. 6, 2024...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance;...

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

WILMETTE, Ill., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage...